AutoImmune Inc. disappointed investors last year when its Myloral bovine myelin for multiple sclerosis failed in Phase III trials in April. Those data were followed by results from two Phase II trials of AIMM's Colloral chicken collagen showing a positive trend, but not statistical significance, for rheumatoid arthritis at doses of 5, 20 or 60 µg in one trial and 20 µg in the second study. Together, the results in MS and RA raised questions about the viability of oral tolerance therapy